Rallybio Corporation (RLYB)
US — Healthcare Sector
Automate Your Wheel Strategy on RLYB
With Tiblio's Option Bot, you can configure your own wheel strategy including RLYB - and automate your put writes, covered calls, and full wheel strategy. Just connect one of the supported brokerages: tastytrade, Schwab, TradeStation or Tradier and go.
Start Your Free Trial NowKey Metrics & Ratings
- symbol RLYB
- Rev/Share 0.1197
- Book/Share 11.1915
- PB 0.4244
- Debt/Equity 0.0031
- CurrentRatio 14.7437
- ROIC -0.6042
- MktCap 25082242.0
- FreeCF/Share -6.2134
- PFCF -0.7167
- PE -1.888
- Debt/Assets 0.0029
- DivYield 0
- ROE -0.2522
- Rating B
- Score 3
- Recommendation Neutral
- P/E Score 1
- DCF Score 5
- P/B Score 4
- D/E Score 4
Recent Analyst Ratings
| Type | Ticker | Analyst Firm | Previous Rating | Current Rating | Previous Price Target | Current Price Target | Date |
|---|---|---|---|---|---|---|---|
| Downgrade | RLYB | H.C. Wainwright | Buy | Neutral | -- | -- | April 9, 2025 |
News
RLYB Ends Pregnancy-Related Rare Disease Program, Stock Tanks
RLYB
Published: April 09, 2025 by: Zacks Investment Research
Sentiment: Negative
Published: April 09, 2025 by: Zacks Investment Research
Sentiment: Negative
Rallybio halts development of RLYB212 in a phase II study for the prevention of fetal and neonatal alloimmune thrombocytopenia. Stock falls.
Read More
Rallybio Stock Plunges After Program For Pediatric Bleeding Disorder Disappoints
RLYB
Published: April 08, 2025 by: Benzinga
Sentiment: Negative
Published: April 08, 2025 by: Benzinga
Sentiment: Negative
Rallybio Corporation RLYB on Tuesday discontinued the RLYB212 program to prevent fetal and neonatal alloimmune thrombocytopenia (FNAIT).
Read More
About Rallybio Corporation (RLYB)
- IPO Date 2021-07-29
- Website https://www.rallybio.com
- Industry Biotechnology
- CEO Stephen Uden
- Employees 15
Rallybio Corporation, a clinical-stage biotechnology company, engages in development and commercialization of life-transforming therapies for patients suffering from severe and rare diseases. Its lead product candidate is RLYB212, a monoclonal anti-HPA-1a antibody which is in Phase II clinical trial for the prevention of fetal and neonatal alloimmune thrombocytopenia (FNAIT); and RLYB211 for the prevention of FNAIT. The company is also developing RLYB114, a pegylated complement factor 5 (C5)-targeted Affibody molecule in preclinical development for the treatment of complement-mediated ophthalmic diseases; RLYB116, an inhibitor of complement component 5 (C5) to treat several diseases of complement dysregulation which has completed phase 1 trial; and RLYB332, a preclinical antibody, for the treatment of severe anemia with ineffective erythropoiesis and iron overload. It entered into a strategic alliance with AbCellera to discover, develop, and commercialize novel antibody-based therapeutics for rare diseases. Rallybio has collaboration with Exscientia for the development of small molecule therapeutics for rare diseases; and collaboration agreement with Johnson & Johnson to provide pregnant individuals therapeutic solutions at risk of fetal and neonatal alloimmune thrombocytopenia. The company was founded in 2018 and is headquartered in New Haven, Connecticut.